

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEPTUNE GENERICS, LLC,
Petitioner,

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner.

Case IPR2018-01494
U.S. Patent No. 8,921,348

**DECLARATION OF HARTMUT DERENDORF, PH.D., IN SUPPORT OF
PATENT OWNER'S RESPONSE**

<p>Corcept Therapeutics, Inc. Exhibit 2014 Neptune Generics, LLC v. Corcept Therapeutics, Inc. Case IPR2018-01494</p>

TABLE OF CONTENTS

	Page
I. INTRODUCTION AND QUALIFICATIONS	1
II. LEGAL STANDARDS	4
A. Obviousness.....	4
B. Relevant Time Period for the Obviousness Analysis.....	6
III. Materials Relied on in Forming My Opinion	7
IV. CLAIM CONSTRUCTION	7
V. PERSON OF ORDINARY SKILL IN THE ART	9
VI. TECHNICAL BACKGROUND	11
A. Pharmacokinetics Overview.....	11
1. PK Parameters And Steady State.....	12
2. Single-Dose Versus Multiple-Dose Studies	14
B. The Difference Between Linear And Non-Linear Pharmacokinetics Profiles	15
1. Linear Pharmacokinetics Profiles	16
2. Non-Linear Pharmacokinetics Profiles.....	16
C. The Relationship Between Pharmacokinetics and Pharmacodynamics.....	19
1. Measuring Blood Serum Levels.....	20
D. The Pharmacokinetics of Mifepristone	21
1. Mifepristone Has A Non-Linear PK Profile	21
2. Mifepristone Has A Complicated Metabolic Profile	25

- VII. PETITIONER’S PRIOR ART REFERENCES28
 - A. Belanoff ’953.....28
 - B. Belanoff ’848.....32
 - C. Belanoff 200234
 - D. Chu & Belanoff36
 - E. Murphy38
 - F. Sitruk-Ware40
- VIII. THE ’348 PATENT45
 - A. The ’348 Invention45
 - B. The ’348 Claims48
 - C. The ’348 File History49
- IX. THE ’348 PATENT CLAIMS ARE NOT OBVIOUS BASED ON THE PRIOR ART51
 - A. Opinions on Ground 155
 - 1. Belanoff ’848 Does Not Disclose, Teach, or Motivate the POSA to Arrive at the Critical 1300 ng/mL Threshold or Use It to Adjust the Patient’s Dose56
 - 2. Belanoff ’848 Teaches that Dosing Should be Adjusted Based on Psychiatric Testing, Not Drug Serum Levels60
 - 3. Belanoff ’848 Does Not Disclose, Teach, or Motivate the Optimization Protocol Described in the ’348 Patent of Monitoring of Mifepristone Serum Levels and Adjusting Dose Based on Drug Levels for Efficacy62
 - 4. Belanoff ’848 Does Not Render Obvious the Dependent Claims66
 - B. Opinions on Ground 267

1.	Neither Belanoff 2002 nor Chu & Belanoff Teach that the Need for Dose Adjustment Should Be Determined Based on Drug Serum Levels	67
2.	Sitruk-Ware Does Not Teach or Motivate a POSA to Target the 1300 ng/mL Level for Efficacy, Or Develop an Optimization Protocol Based on Blood Level	69
3.	Petitioner's Arguments Assuming the Target Therapeutic Level of 1300 ng/mL are Premised on Hindsight.....	81
4.	None of Petitioner's Prior Art References Disclose Mifepristone's PK/PD Relationship, or the Drug Serum Level Required for Efficacy.....	83
5.	Petitioner's Proposed Combinations Do Not Teach or Motivate the '348 Patent's Optimization Protocol	86
6.	A POSA Would Have Had No Reasonable Expectation of Success in Arriving at the 1300 ng/mL Level Due to Mifepristone's Non-Linear PK and Complex Metabolism Complicating Serum Level Determination	89
7.	A POSA Would Have Had No Motivation to Combine the Contraceptive Reference Sitruk-Ware With The Mental Disorder References Belanoff 2002 And Chu & Belanoff.....	94
8.	Belanoff 2002 in View of Chu & Belanoff and Sitruk-Ware Does Not Render Obvious the Dependent Claims.....	96
C.	Opinions on Ground 3	97
D.	Opinions on Ground 4	99
E.	Opinions on Ground 5	100
F.	Opinions on Ground 6	101
X.	CONCLUSION.....	103

I. INTRODUCTION AND QUALIFICATIONS

1. I have been retained by Corcept Therapeutics, Inc. ("Patent Owner" or "Corcept") to provide my opinion on, and explain, factual issues related to the validity of U.S. Patent No. 8,921,348 ("the '348 Patent") in support of Patent Owner's Response in IPR2018-01494.

2. I am being compensated at my standard hourly rate of \$600 per hour, with reimbursement for reasonable expenses, for my work related to the IPR proceeding cited above. My compensation is not dependent on, and in no way affects, the substance of my statements in this Declaration.

3. I am a Distinguished Emeritus Professor in the Department of Pharmaceutics at the University of Florida College of Pharmacy. I also serve as the Principal Scientific Advisor for PK-P'Dyne, Inc., a consulting company.

4. I received my B.S. in Pharmacy in 1976 and Ph.D., *summa cum laude*, in Pharmacy in 1979, both from the University of Münster in Germany. After working as an Assistant Scientist at the University of Münster from 1979-1980, I joined the Department of Pharmaceutics at the University of Florida, first as a Postdoctoral Fellow in 1981 and later as an Assistant Professor in 1983. I became an Associate Professor in 1987, Professor in 1993, and Distinguished Professor in 2003, a title I retained until I retired in 2018. I was named V. Ravi Chandran

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.